Table 3.
Physiologic and Subjective Measures – Summary of Peak Changes (Mean ± SD for 12 Subjects)
| Session 1 | Session 2 | |||
| Measures |
Peak Mean ± SD |
Peak Time (Hr Postdose) |
Peak Mean ± SD |
Peak Time (Hr Postdose) |
| Physiologic Measures | ||||
| Systolic Blood Pressure (mmHg) | 17 ± 8 | 2.2 ± 1.9 | 17 ± 9 | 1.9 ± 1.7 |
| Diastolic Blood Pressure (mmHg) | 10 ± 5 | 2.8 ± 2.4 | 12 ± 6 | 2 ± 2 |
| Heart Rate (beats/min) | 26 ± 10 | 0.8 ± 0.9 | 27 ± 12 | 0.9 ± 1.7 |
| Rate Pressure Product (SBP*HR) | 4224 ± 1638 | 1.4 ± 1.5 | 4437 ± 2333 | 0.9 ± 1.6 |
| Respiration Rate (inhal/min) | 3.8 ± 4.0 | 0.9 ± 1.3 | 3.8 ± 3.6 | 0.4 ± 0.3 |
| Skin Temperature (°C) | -5.4 ± 2.7 | 0.8 ± 0.4 | -5 ± 3.2 | 1.0 ± 1.2 |
| Core Temperature (°C) | 0.7 ± 0.2 | 4.5 ± 1.6 | 0.7 ± 0.5 | 4.2 ± 1.9 |
| Subjective Measures | ||||
| Global Intoxication (0–100) | 57 ± 27 | 0.7 ± 1 | 53 ± 23 | 0.6 ± 0.9 |
| Cocaine Craving (0–100) | 33 ± 25 | 1.1 ± 1.3 | 20 ± 21 | 0.6 ± 0.7 |
| Good Drug Effect (0–100) | 66 ± 23 | 0.9 ± 1.5 | 60 ± 21 | 1 ± 1.3 |
| Bad Drug Effect(0–100) | 46 ± 31 | 1.9 ± 2.3 | 55 ± 25 | 1.4 ± 1.9 |
| POMS Scales | ||||
| Tension (0–28) | 7.5 ± 6.1 | 1 ± 0 | 4.8 ± 3.9 | 1 ± 0 |
| Depression (0–64) | 3 ± 6.5 | 3 ± 0 | 1.5 ± 2.4 | 3 ± 0 |
| Anger (0–28) | 2.8 ± 6.4 | 6 ± 0 | -2.1 ± 5.7* | 6 ± 0 |
| Vigor (0–32) | -3.6 ± 3.4 | 6 ± 0 | -3.9 ± 6.1 | 6 ± 0 |
| Confusion (0–20) | 2.5 ± 2.8 | 6 ± 0 | 2.7 ± 4.7 | 3 ± 0 |
| Fatigue (0–28) | 5.9 ± 5.9 | 6 ± 0 | 2.8 ± 5.3 | 6 ± 0 |
* Significantly different from Session 1 (p < 0.03).
Session 1: First cocaine infusion, performed on day 1, before selegiline administration.
Session 2: Second cocaine infusion, performed on day 11, following one week of selegiline administration by STS patch (6 mg/24 hours). Infusion began 2 hours after application of the selegiline daily patch.